<?xml version="1.0" encoding="UTF-8"?>
<table xmlns="http://www.w3.org/1999/xhtml">
 <caption class="caption">
  <label class="label">Table 2</label>
  <p class="p" xmlns="">Effects of 
   <italic class="italic">N. sativa</italic> and thymoquinone against various types of cancer models and their effects on anticancer agents. 
  </p>
 </caption>
 <thead class="thead">
  <tr class="tr" xmlns="">
   <th colspan="2" align="center" rowspan="1" class="th">Cancer models or effects of anticancer agents</th>
   <th align="left" rowspan="1" colspan="1" class="th">Intervention (s)</th>
   <th align="left" rowspan="1" colspan="1" class="th">Findings (Mechanisms)</th>
   <th align="center" rowspan="1" colspan="1" class="th">References</th>
  </tr>
 </thead>
 <tbody class="tbody">
  <tr class="tr" xmlns="">
   <td rowspan="8" align="left" colspan="1" class="td">
    <italic class="italic">In vitro </italic>studies 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">Doxorubicin-resistant 
    <break class="break"/>human breast cancer cells line (MCF-7/DOX cells) 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (25, 50 or 100 
    <italic class="italic">µ</italic>M) for 48 hours &amp; NSO Nano emulsion 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) Concentration dependent growth inhibition 
    <break class="break"/>(ii) Induce apoptosis, p53 protein 
    <break class="break"/>(iii) Upregulation of PTEN (inhibit PI3K/Akt pathway) 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B125" ref-type="bibr" class="xref">124</xref>, 
    <xref rid="B126" ref-type="bibr" class="xref">125</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Human cervical squamous 
    <break class="break"/>cancer cells 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (1.0 to 30 
    <italic class="italic">μ</italic>g/mL) for 24, 48 and 72 hours 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) More cytotoxic than cisplatin towards this cancerous cell (but less cytotoxicity towards normal cells) 
    <break class="break"/>(ii) Downregulates Bcl-2 protein 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B127" ref-type="bibr" class="xref">126</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Myeloblastic leukemia 
    <break class="break"/>(HL-60 cells) 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ</td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) Induces apoptosis, disrupts mitochondrial membrane potential, triggers the activation of caspases 3, 8 &amp; 9 in HL-60 cells</td>
   <td align="center" rowspan="1" colspan="1" class="td"> [ 
    <xref rid="B128" ref-type="bibr" class="xref">127</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Human bladder cancer cells (T24 and 253J)</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (20-160 
    <italic class="italic">µ</italic>mol/L) for different periods (24h, 48h, and 72h) 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ showed marked cytotoxicity on bladder cancer cells 
    <break class="break"/>(ii) It inhibited cancerous cells rapid multiplication and evoked apoptosis via activation of caspase. 
    <break class="break"/>(iii) TQ also resulted in activation of ER stress, mitochondrial disturbance and enhanced mitochondrial mediated apoptotic path. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B129" ref-type="bibr" class="xref">128</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Renal cell cancer (RCC) cell lines (786-O and ACHN)</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (40 
    <italic class="italic">μ</italic>mol/L) for 24 hours 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ suppressed migration, invasion and epithelial-mesenchymal transition in RCC cells. 
    <break class="break"/>(ii) TQ exhibited significant inhibition of the metastasis of RCC cells through induction of autophagy via AMPK/mTOR signalling. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B130" ref-type="bibr" class="xref">129</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Human renal tubular epithelial cell (HK2) and the human RCC cell lines (769-P &amp; 786-O)</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (0.5, 1, 2.5, 5, 10, 15 &amp; 20 
    <italic class="italic">µ</italic>M) at various durations (0, 24, 48 &amp; 72 h). 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ markedly inhibited the migration and invasion of the human RCC 769-P and 786-O cell lines. 
    <break class="break"/>(ii) TQ also increased the expression of E-cadherin and reduced the expression of Snail, ZEB1 and vimentin at the mRNA as well as protein levels in dose-dependent fashion. 
    <break class="break"/>(iii) As a result, the extents of phosphorylation of hepatic kinase B1 and AMPK were upregulated. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B131" ref-type="bibr" class="xref">130</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Human prostate cancer cell lines (DU145 and C3)</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (2.5, 5.0 &amp; 10 
    <italic class="italic">µ</italic>M) for 24 hours. 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ substantially arrested the proliferation of prostate cancer. 
    <break class="break"/>(ii) It inhibited the migrating and invading capability of prostate cancer DU145 and PC3 cells. 
    <break class="break"/>(iii) TQ also downregulated the expression of TGF- 
    <italic class="italic">β</italic>, Smad2 and Smad3 in prostate cancer cells. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B132" ref-type="bibr" class="xref">131</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Hepatocellular cancer cell line (HepG2)</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (3–24 
    <italic class="italic">µ</italic>M) for 24 hours. 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) Decreased both the no. of viable HepG2 cells and the levels 
    <break class="break"/>(ii) TQ induced cell cycle arrest and apoptosis 
    <break class="break"/>(iii) Increased total antioxidant status (dose dependently) 
    <break class="break"/>(iv) TQ reduced the release of VEGF of HepG2 cells 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B133" ref-type="bibr" class="xref">132</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td colspan="5" rowspan="1" class="td">
    <hr class="hr"/>
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="5" align="left" colspan="1" class="td">
    <italic class="italic">In vivo </italic>studies 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">Diethyl nitrosamine inducedhepatocarcinogenesis in Wistar rats</td>
   <td align="left" rowspan="1" colspan="1" class="td">Ethanolic extract of NS (250 mg/kg) for 5 consecutive days.</td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) The chemical induced increment of liver weight, hepato-somatic indices, serum AFP and VEGF levels, and hepatic HGF 
    <italic class="italic">β</italic> protein expression were significantly reversed by the extract. 
    <break class="break"/>(ii) The histopathological alteration of the livers due to the chemical was decreased in NS extract received rats without harmful effects. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B134" ref-type="bibr" class="xref">133</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Orthotopic model inmice [triple-negative breast cancer (TNBC) cell lines]</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (20 or 100 mg/k) once every 3 days</td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ markedly reduced the growth of MDA-MB-231 tumor. 
    <break class="break"/>(ii) TQ decreased TNBC cell viability and proliferation as well as the migration and invasion of TNBC cells. 
    <break class="break"/>(iii) TQ also downregulated the expression of eEF-2K (via modulation of the NF- 
    <italic class="italic">κ</italic>B/miR-603), Src/FAK, and Akt in TNBC cells. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B135" ref-type="bibr" class="xref">134</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Colon carcinogenesis of rats model</td>
   <td align="left" rowspan="1" colspan="1" class="td">NSO for 14 weeks</td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) NSO revealed a significant antiproliferative activity in both initiation and post-initiation phases 
    <break class="break"/>(ii) Inhibited colon carcinogenesis of rats mainly in the post-initiation stage with no evident of adverse effects 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B136" ref-type="bibr" class="xref">135</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Mouse model of colorectal carcinogenesis &amp; C26 cell</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (5 mg/kg) for 3 weeks &amp; TQ (0, 20, 40, 60 
    <italic class="italic">μ</italic>M) 
    <italic class="italic">in vitro</italic>
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ reduced tumor multiplicity 
    <break class="break"/>(ii) TQ impeded tumor growth and induce apoptosis in HCT116 xenografts 
    <break class="break"/>(iii) Sub-cytotoxic conc. of TQ (40 
    <italic class="italic">μ</italic>M) also reduced C26 cell invasion 
    <break class="break"/>(iv) Anti-neoplastic and pro-apoptotic p53-dependent mechanism 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B137" ref-type="bibr" class="xref">136</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Rat multi-organ 
    <break class="break"/>carcinogenesis 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">NSO for 30 weeks</td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) Reduction in malignant and benign colon tumor sizes, tumors in the lungs and in diverse parts of the alimentary canal principally the oesophagus and fore stomach</td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B138" ref-type="bibr" class="xref">137</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td colspan="5" rowspan="1" class="td">
    <hr class="hr"/>
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td rowspan="4" align="left" colspan="1" class="td">Effect on anti-cancer drugs</td>
   <td align="left" rowspan="1" colspan="1" class="td">Cyclophosphamide 
    <break class="break"/>Induced toxicity (abnormal RF &amp; LFT and reduced Hgb) in rat 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">NSO (1ml/kg) and TQ (10 mg/kg) EOD for 12 days</td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) Substantial reduction in overall cyclophosphamide induced toxicity in both NSO and TQ treated groups.</td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B139" ref-type="bibr" class="xref">138</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Antitumor Effect of TQ and gemcitabine on xenograft mouse and PANC-1, AsPC-1 and BxPC-3 cell lines of pancreatic cancer models,</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (0–50 
    <italic class="italic">µ</italic>mol/L) &amp; 1.0 mg/ mouse daily 
    <break class="break"/>
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ pre-treatment synergistically increased the gemcitabine actions of apoptotic and tumor growth inhibition of pancreatic cancer cells. 
    <break class="break"/>(ii) Concomitant uses resulted in the change of several molecular signaling, including the downregulation of Notch1, NICD associated with up-regulation of PTEN, via the inactivation of Akt/mTOR/S6 signaling. 
    <break class="break"/>(iii) TQ and gemcitabine also induced suppression of anti-apoptotic Bcl-2, Bcl-xL, XIAP and overexpression and activation Caspase-3, Caspase-9, &amp; Bax. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B140" ref-type="bibr" class="xref">139</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Cytotoxicity assay of TQ and paclitaxel on mouse breast cancer cell line (4T1) and animal models</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (6.25, 12.5, 25, 50, &amp; 100 
    <italic class="italic">μ</italic>M) for 24 &amp; 48 hours; (0.64, 2.4 &amp; 3.2 mg/kg of mouse body weight). 
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ induced marked cytotoxicity and apoptosis, while inhibiting wound healing and migration of 4T1 cells. 
    <break class="break"/>(ii) Co-administration of TQ and paclitaxel significantly induced cytotoxicity and apoptosis compared to separate administration. 
    <break class="break"/>(iii) The combination of paclitaxel and the lower dose TQ markedly inhibited the tumor growth. 
    <break class="break"/>(iv) Both agents also modulated the apoptosis genes, p53 and JAK-STAT signaling, while overexpressing the levels of Caspase-3, Caspase-7, and Caspase-12. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B141" ref-type="bibr" class="xref">140</xref>] 
   </td>
  </tr>
  <tr class="tr" xmlns="">
   <td align="left" rowspan="1" colspan="1" class="td">Anti-tumor activity of TQ and topotecan in colorectal cancer cell line (HT-29)</td>
   <td align="left" rowspan="1" colspan="1" class="td">TQ (40, 55 &amp; 60 
    <italic class="italic">µ</italic>M) 
    <break class="break"/>
   </td>
   <td align="left" rowspan="1" colspan="1" class="td">(i) TQ significantly enhanced the anti-tumor effect of non-cytotoxic dose of topotecan. 
    <break class="break"/>(ii) Both drugs induced apoptosis via a p53-independent mechanism, while the expression of p21 was only noted in TQ therapy. 
    <break class="break"/>(iii) TQ improved the effectiveness of topotecan by inhibiting proliferationand lowering toxicity via p53- and Bax/Bcl2-independent mechanisms. 
   </td>
   <td align="center" rowspan="1" colspan="1" class="td">[ 
    <xref rid="B142" ref-type="bibr" class="xref">141</xref>] 
   </td>
  </tr>
 </tbody>
 <tfoot>
  <p charset="fn" class="fn">
   <p class="p" xmlns="">AMPK: Adenosine monophosphate-activated protein kinase, NS: 
    <italic class="italic">Nigella sativa</italic>, NSO: 
    <italic class="italic">Nigella sativa</italic> oil, TQ: Thymoquinone, PTEN: phosphatase and tensin homolog, MCF-7: Michigan Cancer Foundation-7, EOD: every other day, mTOR: Mammalian Target of Rapamycin. 
   </p>
  </p>
 </tfoot>
</table>
